Brief: Iteos Announces Clinically Objective Response Rate At Every Dose In Follow-Up Interim Analysis Of Galaxies Lung-201 Study Of Belrestotug + Dostarlimab In First-Line, Pd-L1 High Non-Small Cell Lung Cancer Patients
14/09/2024 07:33
Sept 14 (Reuters) - Iteos Therapeutics Inc ITOS.O :
* ITEOS ANNOUNCES CLINICALLY MEANINGFUL OBJECTIVE RESPONSE
RATE
OBSERVED AT EVERY DOSE IN FOLLOW-UP INTERIM ANALYSIS OF GALAXIES
LUNG-201 STUDY OF BELRESTOTUG + DOSTARLIMAB IN FIRST-LINE, PD-L1
HIGH NON-SMALL CELL LUNG CANCER PATIENTS
Source text for Eikon: ID:nGNXJmdKD
Further company coverage: ITOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive